Company registration number SC268674 (Scotland)
HOULIHAN PHARMACY LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
HOULIHAN PHARMACY LIMITED
COMPANY INFORMATION
Directors
Mr D Houlihan
Mrs P Houlihan
Secretary
Mrs P Houlihan
Company number
SC268674
Registered office
15 Lorne Road
Hillington
Glasgow
United Kingdom
G52 4HG
Auditor
Azets Audit Services
Titanium 1
Kings Inch Place
Renfrew
United Kingdom
PA4 8WF
HOULIHAN PHARMACY LIMITED
CONTENTS
Page
Strategic report
1
Directors' report
2
Directors' responsibilities statement
3
Independent auditor's report
4 - 6
Profit and loss account
7
Group statement of comprehensive income
8
Group balance sheet
9
Company balance sheet
10
Group statement of changes in equity
11
Company statement of changes in equity
12
Group statement of cash flows
13
Notes to the financial statements
14 - 32
HOULIHAN PHARMACY LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -
The directors present the strategic report for the year ended 31 December 2024.
Review of the business
During the year the company aquired the share capital of Dunnet Healthcare Ltd.
The end of the Brexit transition period has also impacted the flow of imported goods and added significant additional red tape and costs to all imported goods.
Notwithstanding these difficult trading conditions, the results for the year show an operating profit of £891k (2023 - £794k) on turnover of £16.6m (2023 - £14.1m). The group has a balance sheet value of £3.1m at 31 December 2024 (2023 - £2.8m).
The Board is confident that the group's performance and profitability will continue to be strong in 2025 and in subsequent years.
Principal risks and uncertainties
We believe that the company can meet key business risks of competition, both local and national, and also of employee retention.
Development and performance
The company will continue to operate from its existing outlets and appraise any opportunities to add further outlets as they become available.
Key performance indicators
The directors monitor turnover, prescription numbers, gross margin and operating profit at individual pharmacy level and for the company as a whole.
Mr D Houlihan
Director
24 September 2025
HOULIHAN PHARMACY LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
The directors present their annual report and financial statements for the year ended 31 December 2024.
Principal activities
The principal activity of the company continued to be that of the operation of pharmacy retail outlets.
Results and dividends
The results for the year are set out on page 7.
Ordinary dividends were paid amounting to £375,000. The directors do not recommend payment of a further dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Mr D Houlihan
Mrs P Houlihan
Auditor
The auditor, Azets Audit Services, is deemed to be reappointed under section 487(2) of the Companies Act 2006.
Strategic report
The truegroup has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the group's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report. It has done so in respect of financial risk management and exposure to risks and uncertainties.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.
On behalf of the board
Mr D Houlihan
Director
24 September 2025
HOULIHAN PHARMACY LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the group and company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
HOULIHAN PHARMACY LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF HOULIHAN PHARMACY LIMITED
- 4 -
Opinion
We have audited the financial statements of Houlihan Pharmacy Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the group profit and loss account, the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the group's and the parent company's affairs as at 31 December 2024 and of the group's profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
HOULIHAN PHARMACY LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF HOULIHAN PHARMACY LIMITED
- 5 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
the parent company financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
HOULIHAN PHARMACY LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF HOULIHAN PHARMACY LIMITED
- 6 -
Extent to which the audit was considered capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above and on the Financial Reporting Council’s website, to detect material misstatements in respect of irregularities, including fraud.
We obtain and update our understanding of the entity, its activities, its control environment, and likely future developments, including in relation to the legal and regulatory framework applicable and how the entity is complying with that framework. Based on this understanding, we identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. This includes consideration of the risk of acts by the entity that were contrary to applicable laws and regulations, including fraud.
In response to the risk of irregularities and non-compliance with laws and regulations, including fraud, we designed procedures which included:
Enquiry of management and those charged with governance around actual and potential litigation and claims as well as actual, suspected and alleged fraud;
Assessing the extent of compliance with the laws and regulations considered to have a direct material effect on the financial statements or the operations of the entity through enquiry and inspection;
Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations;
Performing audit work over the risk of management bias and override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for indicators of potential bias.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
Greig McKnight (Senior Statutory Auditor)
For and on behalf of Azets Audit Services
24 September 2025
Chartered Accountants
Statutory Auditor
Titanium 1
Kings Inch Place
Renfrew
United Kingdom
PA4 8WF
HOULIHAN PHARMACY LIMITED
GROUP PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
2024
2023
Notes
£
£
Turnover
3
16,567,990
14,097,131
Cost of sales
(10,568,909)
(8,973,796)
Gross profit
5,999,081
5,123,335
Administrative expenses
(5,155,130)
(4,329,575)
Other operating income
47,412
-
Operating profit
4
891,363
793,760
Interest receivable and similar income
8
7,716
Interest payable and similar expenses
9
(328,091)
(168,708)
Profit before taxation
570,988
625,052
Tax on profit
10
(269,512)
(230,256)
Profit for the financial year
301,476
394,796
Profit for the financial year is all attributable to the owners of the parent company.
HOULIHAN PHARMACY LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
2024
2023
£
£
Profit for the year
301,476
394,796
Other comprehensive income
-
-
Total comprehensive income for the year
301,476
394,796
Total comprehensive income for the year is all attributable to the owners of the parent company.
HOULIHAN PHARMACY LIMITED
GROUP BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 9 -
2024
2023
Notes
£
£
£
£
Fixed assets
Goodwill
12
4,592,359
3,197,010
Tangible assets
13
887,105
712,847
5,479,464
3,909,857
Current assets
Stocks
16
856,710
722,830
Debtors
17
3,361,290
3,093,232
Cash at bank and in hand
2,390,111
1,560,280
6,608,111
5,376,342
Creditors: amounts falling due within one year
18
(4,072,414)
(3,133,394)
Net current assets
2,535,697
2,242,948
Total assets less current liabilities
8,015,161
6,152,805
Creditors: amounts falling due after more than one year
19
(5,218,054)
(3,298,118)
Provisions for liabilities
Deferred tax liability
22
111,291
95,347
(111,291)
(95,347)
Net assets
2,685,816
2,759,340
Capital and reserves
Called up share capital
24
3
3
Profit and loss reserves
2,685,813
2,759,337
Total equity
2,685,816
2,759,340
The financial statements were approved by the board of directors and authorised for issue on 24 September 2025 and are signed on its behalf by:
24 September 2025
Mr D Houlihan
Director
Company registration number SC268674 (Scotland)
HOULIHAN PHARMACY LIMITED
COMPANY BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 10 -
2024
2023
Notes
£
£
£
£
Fixed assets
Goodwill
12
2,787,081
3,197,010
Tangible assets
13
852,071
712,847
Investments
14
2,232,967
5,872,119
3,909,857
Current assets
Stocks
16
822,959
722,830
Debtors
17
3,236,861
3,093,232
Cash at bank and in hand
1,991,523
1,560,280
6,051,343
5,376,342
Creditors: amounts falling due within one year
18
(3,859,649)
(3,133,394)
Net current assets
2,191,694
2,242,948
Total assets less current liabilities
8,063,813
6,152,805
Creditors: amounts falling due after more than one year
19
(5,218,054)
(3,298,118)
Provisions for liabilities
Deferred tax liability
22
102,737
95,347
(102,737)
(95,347)
Net assets
2,743,022
2,759,340
Capital and reserves
Called up share capital
24
3
3
Profit and loss reserves
2,743,019
2,759,337
Total equity
2,743,022
2,759,340
As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £358,682 (2023 - £394,797 profit).
The financial statements were approved by the board of directors and authorised for issue on 24 September 2025 and are signed on its behalf by:
24 September 2025
Mr D Houlihan
Director
Company registration number SC268674 (Scotland)
HOULIHAN PHARMACY LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 11 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 January 2023
3
2,739,541
2,739,544
Year ended 31 December 2023:
Profit and total comprehensive income
-
394,796
394,796
Dividends
11
-
(375,000)
(375,000)
Balance at 31 December 2023
3
2,759,337
2,759,340
Year ended 31 December 2024:
Profit and total comprehensive income
-
301,476
301,476
Dividends
11
-
(375,000)
(375,000)
Balance at 31 December 2024
3
2,685,813
2,685,816
HOULIHAN PHARMACY LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 12 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 January 2023
3
2,739,541
2,739,544
Year ended 31 December 2023:
Profit and total comprehensive income for the year
-
394,796
394,796
Dividends
11
-
(375,000)
(375,000)
Balance at 31 December 2023
3
2,759,337
2,759,340
Year ended 31 December 2024:
Profit and total comprehensive income
-
358,682
358,682
Dividends
11
-
(375,000)
(375,000)
Balance at 31 December 2024
3
2,743,019
2,743,022
HOULIHAN PHARMACY LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 13 -
2024
2023
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
31
1,751,053
1,538,626
Interest paid
(328,091)
(168,708)
Income taxes paid
(117,363)
(190,739)
Net cash inflow from operating activities
1,305,599
1,179,179
Investing activities
Purchase of intangible assets
-
(2,649,294)
Purchase of tangible fixed assets
(530,286)
(499,260)
Proceeds from disposal of tangible fixed assets
36,489
11,510
Purchase of subsidiaries, net of cash acquired
(1,884,818)
-
Amounts drawn by directors
205,208
(37,127)
Interest received
7,716
Net cash used in investing activities
(2,165,691)
(3,174,171)
Financing activities
Proceeds from new bank loans
5,550,000
3,516,811
Repayment of bank loans
(3,483,686)
(874,529)
Payment of finance leases obligations
(1,391)
-
Dividends paid to equity shareholders
(375,000)
(375,000)
Net cash generated from financing activities
1,689,923
2,267,282
Net increase in cash and cash equivalents
829,831
272,290
Cash and cash equivalents at beginning of year
1,560,280
1,287,990
Cash and cash equivalents at end of year
2,390,111
1,560,280
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 14 -
1
Accounting policies
Company information
Houlihan Pharmacy Limited (“the company”) is a private limited company domiciled and incorporated in Scotland. The company's registered number and registered office address can be found on the Company Information page.
The group consists of Houlihan Pharmacy Limited and all of its subsidiaries.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Business combinations
In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.
Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.
1.3
Basis of consolidation
The consolidated group financial statements consist of the financial statements of the parent company Houlihan Pharmacy Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.
All financial statements are made up to 31 December 2024. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.
All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 15 -
Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influence, are treated as associates.
Investments in joint ventures and associates are carried in the group balance sheet at cost plus post-acquisition changes in the group’s share of the net assets of the entity, less any impairment in value. The carrying values of investments in joint ventures and associates include acquired goodwill.
If the group’s share of losses in a joint venture or associate equals or exceeds its investment in the joint venture or associate, the group does not recognise further losses unless it has incurred obligations to do so or has made payments on behalf of the joint venture or associate.
Unrealised gains arising from transactions with joint ventures and associates are eliminated to the extent of the group’s interest in the entity.
1.4
Going concern
The directors are required to prepare the statutory financial statements on the going concern basis unless it is inappropriate to presume that the group will continue in business. In satisfaction of this responsibility the directors have considered the group's ability to meet its liabilities as they fall due.
The Directors have made appropriate enquiries and carried out a review of the group’s projections and available banking facilities, taking account of possible changes in trading performance and considering business risk.
The current and future financial position of the group, its cash flows and liquidity position have been reviewed by the directors. The group has a strong cash position as at 31 December 2024. Following this review, the directors have a reasonable expectation that the group has adequate resources to continue in operational existences for the foreseeable future. This includes ensuring the group has sufficient headroom from existing funding facilities to meet any additional cash requirements that would be contingent on a downturn in activity.
As such, the directors consider that it is appropriate to prepare the financial statements on the going concern basis.
1.5
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 16 -
1.6
Intangible fixed assets - goodwill
Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is ten years.
Goodwill, being the amount paid in connection with the acquisition of various businesses, is amortised evenly over its estimated useful life. Where goodwill arose prior to the FRS 102 transition date, the estimated useful life is considered up to a maximum of twenty years.
For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.
1.7
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Leasehold improvements
10% reducing balance
Fixtures and fittings
15% on cost / 20% reducing balance
Computers
25% reducing balance
Motor vehicles
25% on cost / 25% reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.
1.8
Fixed asset investments
Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.
In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.
A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
1.9
Impairment of fixed assets
At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 17 -
1.10
Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.11
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.12
Financial instruments
The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 18 -
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
Derecognition of financial liabilities
Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.
1.13
Equity instruments
Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.
1.14
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 19 -
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.15
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.16
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.17
Leases
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 20 -
1.18
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
2
Judgements and key sources of estimation uncertainty
In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
3
Turnover and other revenue
2024
2023
£
£
Turnover analysed by class of business
NHS income
16,042,456
13,643,268
Counter sales
525,534
453,863
16,567,990
14,097,131
2024
2023
£
£
Other revenue
Interest income
7,716
-
4
Operating profit
2024
2023
£
£
Operating profit for the year is stated after charging/(crediting):
Depreciation of owned tangible fixed assets
410,619
272,833
Depreciation of tangible fixed assets held under finance leases
-
16,417
(Profit)/loss on disposal of tangible fixed assets
(150)
6,932
Amortisation of intangible assets
460,150
299,542
Operating lease charges
206,040
137,280
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 21 -
5
Auditor's remuneration
2024
2023
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the group and company
29,675
23,500
6
Employees
The average monthly number of persons (including directors) employed by the group and company during the year was:
Group
Company
2024
2023
2024
2023
Number
Number
Number
Number
Management and administration
20
24
20
24
Pharmacy shop staff
117
86
107
86
Total
137
110
127
110
Their aggregate remuneration comprised:
Group
Company
2024
2023
2024
2023
£
£
£
£
Wages and salaries
3,151,471
2,662,172
3,116,706
2,662,172
Social security costs
225,435
187,505
223,776
187,505
Pension costs
45,478
42,442
45,021
42,442
3,422,384
2,892,119
3,385,503
2,892,119
7
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
21,487
19,932
Company pension contributions to defined contribution schemes
113
113
21,600
20,045
8
Interest receivable and similar income
2024
2023
£
£
Interest income
Other interest income
7,716
-
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 22 -
9
Interest payable and similar expenses
2024
2023
£
£
Interest on financial liabilities measured at amortised cost:
Interest on bank overdrafts and loans
273,432
167,235
Other finance costs:
Interest on finance leases and hire purchase contracts
54,659
1,473
Total finance costs
328,091
168,708
10
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
259,937
208,729
Adjustments in respect of prior periods
(6,369)
Total current tax
253,568
208,729
Deferred tax
Origination and reversal of timing differences
15,944
21,527
Total tax charge
269,512
230,256
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2024
2023
£
£
Profit before taxation
570,988
625,052
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 23.52%)
142,747
147,012
Tax effect of expenses that are not deductible in determining taxable profit
9,152
9,260
Adjustments in respect of prior years
(6,369)
Fixed asset differences
102,993
72,706
Deferred tax adjustments in respect of prior years
20,989
Remeasurement of deferred tax for changes in tax rates
1,278
Taxation charge
269,512
230,256
Factors that may affect future tax charge
The Chancellor confirmed in the budget on 15 March 2023, that there would be an increase in the top rate of corporation tax to 25% for companies generating taxable profits of more than £250,000. A corporation tax rate of 19% will apply to companies generating taxable profits of less than £50,000. A marginal rate will be applied for profits between these taxable profit bandings. This change became effective from 1 April 2023, therefore increasing the standard tax rate in the year.
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 23 -
11
Dividends
2024
2023
Recognised as distributions to equity holders:
£
£
Interim paid
375,000
375,000
12
Intangible fixed assets
Group
Goodwill
£
Cost
At 1 January 2024
7,818,688
Additions - business combinations
1,855,499
At 31 December 2024
9,674,187
Amortisation and impairment
At 1 January 2024
4,621,678
Amortisation charged for the year
460,150
At 31 December 2024
5,081,828
Carrying amount
At 31 December 2024
4,592,359
At 31 December 2023
3,197,010
Company
Goodwill
£
Cost
At 1 January 2024 and 31 December 2024
7,818,688
Amortisation and impairment
At 1 January 2024
4,621,678
Amortisation charged for the year
409,929
At 31 December 2024
5,031,607
Carrying amount
At 31 December 2024
2,787,081
At 31 December 2023
3,197,010
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 24 -
13
Tangible fixed assets
Group
Leasehold improvements
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 January 2024
2,739,020
432,590
3,171,610
Additions
398,509
186,281
584,790
Business combinations
831
33,281
1,554
760
36,426
Disposals
(110,624)
(110,624)
At 31 December 2024
831
3,170,810
1,554
509,007
3,682,202
Depreciation and impairment
At 1 January 2024
2,191,565
267,198
2,458,763
Depreciation charged in the year
14
237,759
74
172,772
410,619
Eliminated in respect of disposals
(74,285)
(74,285)
At 31 December 2024
14
2,429,324
74
365,685
2,795,097
Carrying amount
At 31 December 2024
817
741,486
1,480
143,322
887,105
At 31 December 2023
547,455
165,392
712,847
Company
Fixtures and fittings
Motor vehicles
Total
£
£
£
Cost
At 1 January 2024
2,739,020
432,590
3,171,610
Additions
398,509
186,281
584,790
Disposals
(110,624)
(110,624)
At 31 December 2024
3,137,529
508,247
3,645,776
Depreciation and impairment
At 1 January 2024
2,191,565
267,198
2,458,763
Depreciation charged in the year
236,527
172,700
409,227
Eliminated in respect of disposals
(74,285)
(74,285)
At 31 December 2024
2,428,092
365,613
2,793,705
Carrying amount
At 31 December 2024
709,437
142,634
852,071
At 31 December 2023
547,455
165,392
712,847
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
13
Tangible fixed assets
(Continued)
- 25 -
The net carrying value of tangible fixed assets includes the following in respect of assets held under finance leases or hire purchase contracts.
Group
Company
2024
2023
2024
2023
£
£
£
£
Motor vehicles
53,753
53,753
14
Fixed asset investments
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Investments in subsidiaries
15
2,232,967
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 January 2024
-
Additions
2,232,967
At 31 December 2024
2,232,967
Carrying amount
At 31 December 2024
2,232,967
At 31 December 2023
-
15
Subsidiaries
Details of the company's subsidiaries at 31 December 2024 are as follows:
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Dunnet Healthcare Ltd
1399 Dumbarton Road, Glasgow, G14 9XS
Ordinary Shares
100.00
This entity is exempt from audit of individual accounts under section 479A of the Companies Act 2006.
16
Stocks
Group
Company
2024
2023
2024
2023
£
£
£
£
Finished goods and goods for resale
856,710
722,830
822,959
722,830
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 26 -
17
Debtors
Group
Company
2024
2023
2024
2023
Amounts falling due within one year:
£
£
£
£
Trade debtors
1,498,544
1,380,885
1,393,057
1,380,885
Corporation tax recoverable
63,743
204,368
63,743
204,368
Other debtors
1,699,037
1,460,277
1,683,526
1,460,277
Prepayments and accrued income
99,966
47,702
96,535
47,702
3,361,290
3,093,232
3,236,861
3,093,232
18
Creditors: amounts falling due within one year
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Bank loans
20
350,808
162,443
350,808
162,443
Obligations under finance leases
21
11,436
310
11,436
310
Trade creditors
2,511,323
2,045,344
2,352,445
2,045,344
Amounts owed to group undertakings
100,868
Corporation tax payable
322,237
221,206
211,671
221,206
Other taxation and social security
82,921
77,943
82,498
77,943
Other creditors
352,926
292,968
329,037
292,968
Accruals and deferred income
440,763
333,180
420,886
333,180
4,072,414
3,133,394
3,859,649
3,133,394
19
Creditors: amounts falling due after more than one year
Group
Company
2024
2023
2024
2023
Notes
£
£
£
£
Bank loans and overdrafts
20
5,176,067
3,298,118
5,176,067
3,298,118
Obligations under finance leases
21
41,987
41,987
5,218,054
3,298,118
5,218,054
3,298,118
20
Loans and overdrafts
Group
Company
2024
2023
2024
2023
£
£
£
£
Bank loans
5,526,875
3,460,561
5,526,875
3,460,561
Payable within one year
350,808
162,443
350,808
162,443
Payable after one year
5,176,067
3,298,118
5,176,067
3,298,118
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
20
Loans and overdrafts
(Continued)
- 27 -
The loan in the prior year was repaid in October 2024 with a new loan being drawn down. The new term loan is repayable over five years in quarterly instalments.
The loan at the reporting date was secured by a floating charge over the assets of the company.
21
Finance lease obligations
Group
Company
2024
2023
2024
2023
£
£
£
£
Future minimum lease payments due under finance leases:
Within one year
11,436
310
11,436
310
In two to five years
41,987
41,987
53,423
310
53,423
310
Finance lease payments represent rentals payable by the company or group for certain items of plant and machinery. Leases include purchase options at the end of the lease period, and no restrictions are placed on the use of the assets. The average lease term is 4 years. All leases are on a fixed repayment basis and no arrangements have been entered into for contingent rental payments.
22
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:
Liabilities
Liabilities
2024
2023
Group
£
£
Accelerated capital allowances
111,981
96,099
Short term timing differences
(690)
(752)
111,291
95,347
Liabilities
Liabilities
2024
2023
Company
£
£
Accelerated capital allowances
103,427
96,099
Short term timing differences
(690)
(752)
102,737
95,347
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
22
Deferred taxation
(Continued)
- 28 -
Group
Company
2024
2024
Movements in the year:
£
£
Liability at 1 January 2024
95,347
95,347
Charge to profit or loss
15,944
7,390
Liability at 31 December 2024
111,291
102,737
The deferred tax liability set out above is expected to reverse within 12 months and relates to accelerated capital allowances that are expected to mature within the same period.
23
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
45,478
42,442
A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.
24
Share capital
Group and company
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
2
2
2
2
A Ordinary share of £1 each
1
1
1
1
3
3
3
3
The company has two classes of ordinary shares. The company may declare different rates of dividend in respect of each class of share. Ordinary shares have full rights in the company with respect to distributions and voting. A Ordinary shares are only entitled to their nominal value plus 10% on distributions. These shares do not carry voting rights.
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 29 -
25
Acquisition of a business
On 29 October 2024 the group acquired 100% percent of the issued capital of Dunnet Heathcare Ltd.
Book Value
Adjustments
Fair Value
Net assets acquired
£
£
£
Intangible assets
91,990
-
91,990
Property, plant and equipment
36,426
-
36,426
Inventories
33,751
-
33,751
Trade and other receivables
449,831
-
449,831
Cash and cash equivalents
137,107
-
137,107
Trade and other payables
(173,773)
-
(173,773)
Tax liabilities
(105,874)
-
(105,874)
Total identifiable net assets
469,458
-
469,458
Goodwill
1,763,509
Total consideration
2,232,967
The consideration was satisfied by:
£
Cash
1,980,000
Deferred consideration
211,042
Professional fees
41,925
2,232,967
The goodwill arising on the acquisition of the business is attributable to the anticipated profitability of the company acquired and future operating synergies from the combination. The useful life has been assessed by management as 10 years.
The directors are satisfied that the fair value of the assets and liabilities acquired in the business combination was equivalent to their book value and that no separately identifiable intangible assets were acquired.
Contribution by the acquired business for the reporting period included in the group statement of comprehensive income since acquisition:
£
Turnover
214,650
Loss after tax
(13,121)
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 30 -
26
Operating lease commitments
Lessee
At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
Group
Company
2024
2023
2024
2023
£
£
£
£
Within one year
209,790
141,950
209,790
141,950
Between two and five years
635,691
487,256
635,691
487,256
In over five years
445,416
492,365
445,416
492,365
1,290,897
1,121,571
1,290,897
1,121,571
27
Capital commitments
Amounts contracted for but not provided in the financial statements:
Group
Company
2024
2023
2024
2023
£
£
£
£
Acquisition of tangible fixed assets
27,866
550,969
27,866
550,969
28
Related party transactions
The following amounts were outstanding at the reporting end date:
Amounts due from related parties
2024
2023
Balance
Balance
£
£
Group
Entities with control, joint control or significant influence over the group
1,555,604
512,853
Company
Entities with control, joint control or significant influence over the company
1,555,604
512,853
Other information
At 31 December 2024 the group and company was owed £15,000 (2023: £15,000) by family members of the directors.
There were no other related party transactions during the year or balances at the year end.
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 31 -
29
Directors' transactions
Advances or credits have been granted by the company to its directors as follows:
Dividends totalling £375,000 (2023 - £375,000) were paid in the year in respect of shares held by the company's directors.
Description
% Rate
Opening balance
Amounts advanced
Amounts repaid
Closing balance
£
£
£
£
Loan
-
368,552
910,077
(375,000)
903,629
368,552
910,077
(375,000)
903,629
30
Controlling party
The company was under control of the directors throughout the year.
31
Cash generated from group operations
2024
2023
£
£
Profit for the year after tax
301,476
394,796
Adjustments for:
Taxation charged
269,512
230,256
Finance costs
328,091
168,708
Investment income
(7,716)
(Gain)/loss on disposal of tangible fixed assets
(150)
6,932
Amortisation and impairment of intangible assets
460,150
299,542
Depreciation and impairment of tangible fixed assets
410,619
289,250
Movements in working capital:
Increase in stocks
(100,129)
(4,840)
Increase in debtors
(164,060)
(280,470)
Increase in creditors
253,260
434,452
Cash generated from operations
1,751,053
1,538,626
HOULIHAN PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 32 -
32
Analysis of changes in net debt - group
1 January 2024
Cash flows
New finance leases
31 December 2024
£
£
£
£
Cash at bank and in hand
1,560,280
829,831
-
2,390,111
Borrowings excluding overdrafts
(3,460,561)
(2,066,314)
-
(5,526,875)
Obligations under finance leases
(310)
1,391
(54,504)
(53,423)
(1,900,591)
(1,235,092)
(54,504)
(3,190,187)
2024-12-312024-01-01falsefalseCCH SoftwareCCH Accounts Production 2025.100Mr D HoulihanMrs P HoulihanMrs P HoulihanfalseSC268674bus:Consolidated2024-01-012024-12-31SC2686742024-01-012024-12-31SC268674bus:Director12024-01-012024-12-31SC268674bus:CompanySecretaryDirector12024-01-012024-12-31SC268674bus:CompanySecretary12024-01-012024-12-31SC268674bus:Director22024-01-012024-12-31SC268674bus:RegisteredOffice2024-01-012024-12-31SC268674bus:Consolidated2024-12-31SC2686742024-12-31SC268674bus:Consolidated2023-01-012023-12-31SC2686742023-01-012023-12-31SC268674core:Goodwillbus:Consolidated2024-12-31SC268674core:Goodwillbus:Consolidated2023-12-31SC268674core:Goodwill2024-12-31SC268674core:Goodwill2023-12-31SC268674bus:Consolidated2023-12-31SC2686742023-12-31SC268674core:LeaseholdImprovementsbus:Consolidated2024-12-31SC268674core:FurnitureFittingsbus:Consolidated2024-12-31SC268674core:ComputerEquipmentbus:Consolidated2024-12-31SC268674core:MotorVehiclesbus:Consolidated2024-12-31SC268674core:LeaseholdImprovementsbus:Consolidated2023-12-31SC268674core:FurnitureFittingsbus:Consolidated2023-12-31SC268674core:ComputerEquipmentbus:Consolidated2023-12-31SC268674core:MotorVehiclesbus:Consolidated2023-12-31SC268674core:FurnitureFittings2024-12-31SC268674core:MotorVehicles2024-12-31SC268674core:FurnitureFittings2023-12-31SC268674core:MotorVehicles2023-12-31SC268674core:ShareCapitalbus:Consolidated2024-12-31SC268674core:ShareCapitalbus:Consolidated2023-12-31SC268674core:RetainedEarningsAccumulatedLossesbus:Consolidated2023-12-31SC268674core:ShareCapital2024-12-31SC268674core:ShareCapital2023-12-31SC268674core:RetainedEarningsAccumulatedLosses2024-12-31SC268674core:RetainedEarningsAccumulatedLosses2023-12-31SC268674core:ShareCapitalbus:Consolidated2022-12-31SC268674core:RetainedEarningsAccumulatedLossesbus:Consolidated2022-12-31SC268674core:ShareCapital2022-12-31SC268674core:RetainedEarningsAccumulatedLosses2022-12-31SC268674bus:Consolidated2022-12-31SC268674core:Goodwill2024-01-012024-12-31SC268674core:LeaseholdImprovements2024-01-012024-12-31SC268674core:FurnitureFittings2024-01-012024-12-31SC268674core:ComputerEquipment2024-01-012024-12-31SC268674core:MotorVehicles2024-01-012024-12-31SC268674core:UKTaxbus:Consolidated2024-01-012024-12-31SC268674core:UKTaxbus:Consolidated2023-01-012023-12-31SC268674bus:Consolidated12024-01-012024-12-31SC268674bus:Consolidated12023-01-012023-12-31SC268674bus:Consolidated22024-01-012024-12-31SC268674bus:Consolidated22023-01-012023-12-31SC268674core:Goodwillbus:Consolidated2023-12-31SC268674core:Goodwill2023-12-31SC268674core:Goodwillbus:Consolidated2024-01-012024-12-31SC268674core:LeaseholdImprovementsbus:Consolidated2023-12-31SC268674core:FurnitureFittingsbus:Consolidated2023-12-31SC268674core:ComputerEquipmentbus:Consolidated2023-12-31SC268674core:MotorVehiclesbus:Consolidated2023-12-31SC268674bus:Consolidated2023-12-31SC268674core:FurnitureFittings2023-12-31SC268674core:MotorVehicles2023-12-31SC2686742023-12-31SC268674core:LeaseholdImprovementsbus:Consolidated2024-01-012024-12-31SC268674core:FurnitureFittingsbus:Consolidated2024-01-012024-12-31SC268674core:ComputerEquipmentbus:Consolidated2024-01-012024-12-31SC268674core:MotorVehiclesbus:Consolidated2024-01-012024-12-31SC268674core:Subsidiary12024-01-012024-12-31SC268674core:Subsidiary112024-01-012024-12-31SC268674core:CurrentFinancialInstruments2024-12-31SC268674core:CurrentFinancialInstruments2023-12-31SC268674core:CurrentFinancialInstrumentsbus:Consolidated2024-12-31SC268674core:CurrentFinancialInstrumentsbus:Consolidated2023-12-31SC268674core:WithinOneYearbus:Consolidated2024-12-31SC268674core:WithinOneYearbus:Consolidated2023-12-31SC268674core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-31SC268674core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-31SC268674core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-12-31SC268674core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2023-12-31SC268674core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-31SC268674core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-31SC268674core:Non-currentFinancialInstrumentsbus:Consolidated2024-12-31SC268674core:Non-currentFinancialInstrumentsbus:Consolidated2023-12-31SC268674core:Non-currentFinancialInstruments2024-12-31SC268674core:Non-currentFinancialInstruments2023-12-31SC268674core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-12-31SC268674core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2023-12-31SC268674core:WithinOneYear2024-12-31SC268674core:WithinOneYear2023-12-31SC268674core:BetweenTwoFiveYearsbus:Consolidated2024-12-31SC268674core:BetweenTwoFiveYearsbus:Consolidated2023-12-31SC268674core:BetweenTwoFiveYears2024-12-31SC268674core:BetweenTwoFiveYears2023-12-31SC268674bus:PrivateLimitedCompanyLtd2024-01-012024-12-31SC268674bus:FRS1022024-01-012024-12-31SC268674bus:Audited2024-01-012024-12-31SC268674bus:ConsolidatedGroupCompanyAccounts2024-01-012024-12-31SC268674bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP